Pentwater Capital Management LP Arvinas, Inc. Transaction History

Pentwater Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $2.41 Million - $3.26 Million	-40,000 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$65.85 - $96.21 $131,700 - $192,420	2,000 Added 5.26%	40,000 $3.29 Million
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $483,120 - $711,942	-6,600 Reduced 14.8%	38,000 $3.12 Million
Q1 2021 May 17, 2021	SELL	$58.19 - $91.37 $459,701 - $721,823	-7,900 Reduced 15.05%	44,600 $2.95 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $1.06 Million - $4.46 Million	52,500 New	52,500 $4.46 Million
Q2 2019 Aug 14, 2019	SELL	$15.96 - $23.8 $355,908 - $530,740	-22,300 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$13.55 - $23.79 $642,270 - $1.13 Million	-47,400 Reduced 68.01%	22,300 $329,000
Q4 2018 Feb 14, 2019	BUY	$11.19 - $18.56 $108,543 - $180,032	9,700 Added 16.17%	69,700 $896,000
Q3 2018 Nov 14, 2018	BUY	$16.05 - $16.87 $963,000 - $1.01 Million	60,000 New	60,000 $1.01 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Pentwater Capital Management LP with notifications on news.